Nuventra, CATO SMS | May 27, 2021
CATO SMS, a global provider of regulatory and clinical research services, announced today the acquisition of Nuventra, Inc., to expand its offering into the critical area of clinical pharmacology. Nuventra, headquartered in Durham, North Carolina, is a leading company in clinical pharmacology science and services. The acquisition expands CATO SMS's portfolio of specialized solutions that help biopharmaceutical companies with drug development by providing a key set of skills targeted at significantly reducing development risk, costs, and timelines.
CATO SMS now provides customers cutting-edge clinical pharmacology services such as strategic consulting, pharmacokinetics/pharmacodynamics (PK/PD), pharmacometrics (population PK), and biosimulation. Nuventra is well-known for its track record of transforming complex data into meaningful insights for over 650 biopharmaceutical companies across a wide range of therapeutic areas. Its team of scientific experts and senior consultants use the most advanced mathematical modeling tools in the industry to inform clinical design and predict trial outcomes.
Nuventra's range of solutions include:
• pharmacokinetics and pharmacodynamics (PK/PD), which describes the movement of drugs through the body from absorption to elimination (PK), as well as the body's biological response to drugs (PD) to determine optimal dosing paradigms, safety margins, and efficacy characteristics.
• population pharmacokinetics (popPK and popPK/PD), which studies the variability in drug concentrations among individuals in a group of interest receiving clinically relevant doses of a drug.
• clinical pharmacology strategic consulting, which includes overall and targeted clinical pharmacology strategy in support of marketing applications for drugs and biologics.
• physiologically based pharmacokinetic (PBPK), which incorporates blood flow and tissue composition of organs to predict the absorption, distribution, metabolism, and excretion (ADME) of drugs.
• quantitative systems pharmacology (QSP), which models the interplay of the drug (dose, dosing regimen, etc.) with target biology, using computational systems to characterize the interaction between drugs, biological systems, and disease processes.
• model-informed drug development (MIDD), which uses modeling techniques to improve the decision-making process in drug development, thereby leading to clinical trial efficiencies and, in some cases, replacing trials altogether.
Nuventra is the pharmaceutical industry's preferred provider of clinical pharmacology, pharmacokinetics, and pharmacometrics consulting services. Nuventra provides pharmaceutical companies and contracts research organizations (CROs) with unique access to a hands-on team of industry-leading consultants with extensive experience in complex studies and analyses. By taking complex pharmacokinetic and pharmacometrics concepts and making them understandable and usable for common sense drug development, we embrace the notion that simplicity and clarity lead to smart decisions.
About CATO SMS
CATO SMS is a provider of specialized clinical research solutions formed in 2019 by the merger of Cato Research and SMS-oncology. CATO SMS, with over 30 years of professional experience focusing on the needs of small and emerging biopharmaceutical companies, effectively designs and executes studies from strategy to approval in complex indications and modalities throughout a wide range of therapeutic areas, with a proven center of excellence in oncology. The regulatory, therapeutic, and operational expertise of CATO SMS enables the company to meet and exceed expectations.
Insilico Medicine | March 25, 2022
A clinical-stage end-to-end artificial intelligence driven drug discovery firm, Insilico Medicine announced the formation of a strategic partnership with EQRx, a company dedicated to creating and delivering novel medications to patients at much-reduced costs.
The cooperation will use Insilico's Pharma.AI technology to accelerate the design and creation of de novo small molecules and EQRx's clinical development and commercialization experience. In addition, EQRx and Insilico will form a co-development partnership in which each party will get a profit share according to its investment level.
The collaborative agreement identifies and selects up to three therapeutic targets using Insilico's AI-powered platform, Pharma. AI. From small molecule hit identification through lead optimization and preclinical candidate nomination, Insilico will guide the drug discovery process. EQRx will be in charge of clinical development, regulatory affairs, and commercialization. In addition, Insilico may invest in the product candidate(s) at different phases of clinical outcome in exchange for enhanced commercialization income.
"Both EQRx and Insilico Medicine strive to accelerate the discovery and development of new medicines and make effective therapeutics more accessible and affordable. This partnership will combine our end-to-end AI-powered drug discovery capabilities with EQRx's innovative partnership model and expertise in clinical development and patient access to accelerate innovative therapies' discovery and development, "
Alex Zhavoronkov, Ph.D., founder and founder CEO of Insilico Medicine
"We are pleased to partner with Insilico Medicine, a leader in AI-based drug discovery," said Carlos Garcia-Echeverria, Ph.D., chief of Rx Creation at EQRx. "This collaboration will further expand our early-stage R&D efforts to fuel potential pipeline growth as we continue to apply the best of today's innovation in biomedical sciences and digital solutions to discover high-quality, innovative, and more affordable medicines."
International Medical Industries, Inc. | February 28, 2022
IMI bolsters expertise in secure drug delivery products with the release of new Prep-Lock Tamper Evident Cap for ENFit® and Oral Syringes with incorporated Radio Frequency Identification (RFID) technology.
IMI's Prep-Lock line of Tamper Evident Products helps ensure medication safety from pharmacy to patient. The DoseID certified RFID Technology presents an opportunity to augment the proven benefits of tamper-evident products. "RFID technology represents the future of inventory management and medication safety. This technology aligns perfectly with IMI's core business strategy of providing drug security solutions to healthcare institutions worldwide," says Bryan McGurn IMI Senior Vice President of Sales & Marketing.
Prep-Lock Tamper Evident Caps are an established method for providing safeguards to ensure medication safety. Tamper Evident Caps for ENFit and Oral Syringes offer the same high-value risk mitigation as the IV Caps utilized by 84% of the top outsource compounders in the US. RFID technology enables real-time scanning that optimizes inventory management, efficiency, and medication safety while creating quantifiable pharmaceutical supply chain benefits by providing item-level inventory visibility. Every drug secured with a Tamper Evident Cap featuring RFID is trackable throughout its entire lifecycle. These two powerful technologies in combination enhance workflow efficiencies, eliminate time-consuming manual inventory control processes, provide assistance with growing regulatory demand, and supply a comprehensive strategy to prevent, detect, and resolve drug diversion events. In addition, Tamper Evident Caps with incorporated RFID technology offer a significant reduction in RFID implementation costs.
IMI joined DoseID, a consortium of RFID proponents in 2020 to support the interoperability, quality, and performance of RFID tagged products. The DoseID RFID tag, now incorporated in the Prep-Lock Tamper Evident Cap, is certified by Auburn University RFID Lab's ARC Program to ensure the high standards set by the DoseID consortium are met and that those standards meet the needs of the healthcare industry.
"We're using RFID tags to automate some of our inventory management and get better insight into inventory movement," says Dr. Paul Stranges, PharmD, BCACP, AE-C Clinical Assistant Professor at the Department of Pharmacy Practice at The University of Chicago's College of Pharmacy. "It really helps our efficiency." Incorporating RFID technology in IMI's Tamper Evident Cap delivers a significant advantage in supply chain management. They offer both hospitals and outsource compounding operations an efficient and cost-saving method for applying RFID benefits to their drug preparations.